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Summary
Purpose: In infants with frequent therapy resistant seizures (TRS-infants), clinical
detection of pyridoxine-dependency (PD) or -responsiveness (PR) occurs by empirical
intravenous (IV) pyridoxine administration during recording of the EEG. However, in
undiagnosed TRS-infants it is still unclear to what extent EEG alterations by pyridox-
ine-IV are attributable to PD/PR or to non-specific responses. Before EEG alterations
by pyridoxine-IV can be ascribed to PD/PR, these non-specific responses should be
excluded first.
Methods: In 10 TRS-infants under 1 year of age, we determined the EEG effect by
pyridoxine-IV on the EEG-recording.
Results: After pyridoxine-IV administration, our data indicate declined (10—15%;
p < 0.05) EEG-amplitudes and total power (magnitude/frequency-band) at frontal,
central and centro-temporal electrodes.
Conclusion: In TRS-infants, pyridoxine-IVaffects EEG-amplitude and -total power in a
non-specific way, which does not identify PD/PR.
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Pyridoxine is a common cofactor involved in many
metabolic pathways of the brain.1 In a small, het-
erogeneous group of infants with therapy resistant. Published by Elsevier Ltd. All rights reserved.
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may stop or attenuate seizures.2 According to
well-defined clinical criteria, this response can be
characterized as pyridoxine-dependency (PD) or as
pyridoxine-responsiveness (PR), respectively.2 PD is
characterized by: (1) seizures persisting despite
administration of at least two anti-epileptic drugs,
(2) seizure cessation after pyridoxine administration,
(3) complete seizure control by pyridoxine mono-
therapy, and (4) seizure recurrence after pyridoxine
withdrawal.3 The term PR is reserved for infants that
show reduced seizure activity by pyridoxine, but in
whom the seizures do not meet all PD criteria.2,4
Different enzyme deficiencies may explain the
effect by pyridoxine (or its active metabolite pyr-
idoxal phosphate) on seizure activity,5,6 including
one in which shortage of pyridoxal phosphate is
linked to an impaired conversion of (the excitatory
amino acid) glutamate into (inhibitory) GABA. In a
neonatal subgroup, this has been related to a muta-
tion in the PNPO gene, encoding for pyridox(am)ine-
50-phosphate oxidase (which converts pyridoxine
into pyridoxal phosphate).7 As a consequence,
empirical administration of pyridoxal phosphate
(instead of pyridoxine) is increasingly recom-
mended, especially in neonates and in children with
West syndrome.7—9 Another important PD-subgroup
is ascribed to a-aminoadipine semialdehyde
[ALDH7A1 (antiquitin)] deficiency. These patients
can be diagnosed by mutation analysis of the
ALDH7A1 gene10 and by biochemical analysis [of
pipecolic acid11,12 and of alpha amino adipic semi-
aldehyde (alpha-AASA)10 concentrations (in blood/
CSF and in urine, respectively)]. In these patients,
PD is caused by chemical inactivation of pyridoxine
phosphate (due to reaction with a-aminoadipine
semialdehyde).6,10 A similar chemical inactivation
of pyridoxine is also involved in PD patients due to
hyperprolinemia type II.13
Although these PD/PR-subgroups can be identi-
fied, time is needed for detection. Furthermore,
incomplete diagnostic knowledge of other PD/PR-
subgroups may still hamper fast and accurate recog-
nition.5,14 To facilitate recognition of PD/PR among
TRS-infants, pyridoxine is empirically supplied
according to different test-protocols. In TRS-infants
with low seizure frequencies, PD/PR is clinically
characterized by the response after oral pyridoxine
administration (for at least 14 days) and subsequent
withdrawal.2 To optimize identification of PD/PR,
EEG recordings before- and after-pyridoxine admin-
istration are preferably taken into account.5 In TRS-
infants with high seizure frequencies (or status
epilepticus), a test dose of pyridoxine-IV is adminis-
tered.3 Within minutes after pyridoxine infusion,
seizure activity may stop in PD/PR.3,15 To allow fastand accurate detection of the response, pyridoxine-
IV guidelines recommend simultaneous recording of
the EEG.2,3 In PD/PR patients, EEG recordings pre-
ceding pyridoxine administration may reveal focal
(frontal, parietal or temporal) bursts of sharp slow
wave activity (1—4 Hz) and bilateral synchronous
discharges.3 In PD/PR patients, this epileptic activ-
ity may disappear within 5 min after pyridoxine-IV
administration2 and the EEG amplitude may reduce
or flatten.1 Although rapid normalization of the EEG
is generally expected,5 normalization of the EEG
may be incomplete16 or delayed (for hours-days).2,15
Especially in PD/PR children with associated mor-
bidity such as asphyxia, intracranial hemorrhages or
multi-system involvement2 this could be the case.
In perspective of this clinical variability, EEG con-
trol data during pyridoxine-IV in TRS-infants (without
PD/PR) seem important. However, such EEG control
data have not been reported yet. For instance, it is
still unknown whether pyridoxine-IV also induces
EEG-alterations that do not identify PD/PR. Such
‘‘non-specific’’ effects should be taken into account
before EEG-alterations are attributed to PD/PR. To
evaluate whether such ‘‘non-specific’’ EEG-altera-
tions occur, we studied EEG recordings in TRS-infants
during an empirical test dose of pyridoxine-IV.Methods
Patients
At the University Medical Center Groningen, we
retrospectively collected digital EEG data of 10
TRS-infants (of less than 1 year of age) that received
a clinical trial of pyridoxine-IV between 2001 and
2004. The medical ethical committee decided that,
according to Dutch legislation, no approval is
needed for this kind of retrospective data collec-
tion. Informed consent from the parents of all
included infants was obtained. TRS was defined as
intractable seizures despite administration of two
first-line anti-epileptic drugs in adequate dosages.
Study design
Before and after administration of 100 mg pyridox-
ine-IV, EEG segments were digitally compared for
average background amplitude. Thereafter, altera-
tions of delta (0—3 Hz), theta (4—8 Hz) and beta
(13—30 Hz) frequency-bands were separately
assessed regarding amplitude, total-and relative-
power. Total power reflects the magnitude of back-
ground activity for an individual frequency band.
Relative power indicates the relative contribution of
a frequency-band to the entire spectrum.17 Both
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doxine-IV, two separate 1 min EEG segments with
identical vigilance states were assessed. These
states (asleep or quietly awake) were identified
by EEG and clinical observation. Only EEG segments
of identical vigilance states were compared.
Digital EEG recording and analysis
Digital EEG recording and analysis was performed
using Brainlab Version 4.00-0.00 and Brain Vision
Analyzer Version 1.030002. All digital EEGs involved
a 21-channel recording according to the international
10/20 system. Bipolar recordings were evaluated at
frontal (F3-F4), centro-temporal (T3-C3; C4-T4),
central (C3-C4), and occipital (O1-O2) electrodes.
Selected segments before and after pyridoxine-IV
were digitally compared regarding amplitude and
total power of delta (0—3 Hz), theta (4—8 Hz) and
beta (13—30 Hz) frequency-bands. For power calcu-
lations, a Fast Fourier Transform was applied.
To assess a potential shift in frequency-bands by
pyridoxine-IV, relative power per frequency-band
was calculated according to the formula:
prelative½ f1; f2 ¼
p½ f1; f2
p½0; 50  100%
p[f1,f2] is the total power in the frequency-band
between f1 and f2 Hz.
For further reading on Power Analysis, see also
ref. 17.
Statistical analysis
Regarding amplitude and power analysis, EEG seg-
ments before and after pyridoxine-IVwere compared
by the Wilcoxon signed rank test. Mann—Whitney UTable 1 Clinical data of included patients
Case AED before/during
IV pyridoxine
Epilepsy
syndrome
Seizure
classifi
1 B, PB — C, G
2 B, LD, PB — S, G
3 B, LD — S, G
4 B, LTG, VPA — C, Pc
5 B, PB — S, G
6 B, LD, PB — S, G
7 B, PB — C, PsG
8 B, LTG, VGB, VPA West C, G
9 B, PB, VPA — C, PsG
10 B, VPA West C, G
Abbreviations: AED = antiepileptic drug treatment; IV = intraven
LTG = lamotrigine; VPA = valproic acid; VGB = vigabatrin; C = crypto
PsG = partial secondarily generalized; multif.myo. = multifocal my
natal months; –— = absent.test was applied for EEG comparison between infants
that were awake or asleep.Results
Clinical data
Table 1 shows patient characteristics of the ten
included infants. CSF GABA concentrations before
pyridoxine administration were within the normal
range (>2 ng/ml). Three neonates were born after
severe or moderate fetal distress (cases 1, 3 and 7).
Median age of seizure onset was at postnatal day 1
(range 0—10 months). Median duration between
seizure onset and pyridoxine-IV was 14 days (range
1 day to 8 months).
Two patients (case 1 and 3) were clinically char-
acterized as PR. Although seizures did not disappear
by pyridoxine monotherapy alone,2 both infants
showed attenuated seizure activity by subsequent
oral pyridoxine administration. In each infant, pyr-
idoxinewithdrawalwas performed twice, resulting in
seizure recurrence within 24 h (for detailed descrip-
tionof case1, seealso ref. 16).At2 yearsof age, eight
patients were still on anti-epileptic drugs and seizure
control was achieved in five patients.
EEG findings
Pyridoxine-IV decreased amplitude ( p < 0.05) at
central, centro-temporal and frontal electrodes
[C3-C4: median 13% (49 to +15%; Fig. 1); C3-
T3: median 15% (58 to +5%) and F3-F4: median
11% (64 to +19%)]. In 8 of 10 infants, alterations
were visible at all (n = 2) or at selective (n = 6)
electrode-positions.cation
Seizure
type
Seizure
onset
Age at IV
pyridoxine
Tonic clonic 0 d 12 d
Subtle 0 d 2 d
Misc. 0 d 3 d
Subtle 0 d 8 m
Tonic clonic 1 d 7 d
Tonic clonic 1 d 13 d
Multif.myo. 3 m 3 m
Misc. 3 m 6 m
Tonic clonic 4 m 7 m
Misc. 10 m 11 m
ous; B = benzodiazepines; PB = phenobarbital; LD = lidocaine;
genic; G = generalized; S = symptomatic; Pc = partial complex;
oclonic; misc. = miscellaneous; d = postnatal day(s); m = post-
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Figure 1 (a) Effect of pyridoxine IV on the EEG-amplitude at C3-C4. Before (horizontal axis, left) and after (horizontal
axis, right) administration of pyridoxine-IV, central amplitude alterations (inmV, at vertical axis) are indicated. At central
electrodes, amplitudes declined significantly by pyridoxine IV. (b) Relative effect of pyridoxine-IV on the EEG-amplitude
at central electrodes. The pyridoxine-IVeffect on amplitude is expressed as percentage of initial value, before pyridoxine
administration. At central electrodes, pyridoxine-IV administration decreased the EEG-amplitude ( p < 0.05). Median
decline is indicated by an arrow. The two PR infants, cases 1 and 3, are separately indicated by dashed lines.The pyridoxine-IV effect on total power was
assessed for delta, theta and beta frequency-bands.
In the delta frequency-band, total power declined
( p < 0.05) at central and centro-temporal electro-
des [C3-C4 (Fig. 2a): median 14% (47 to +15%);
C3-T3: median 14% (47 to +6%)]. In the theta
frequency-band, total power declined ( p < 0.05) at
central and frontal electrodes [C3-C4 (Fig. 2b):Figure 2 Relative effect of pyridoxine-IV on total power at C
theta (b) and beta (c) frequency-bands is expressed as percen
central electrodes, pyridoxine-IV administration decreased t
frequency bands ( p < 0.05). Median declines are indicated by
indicated by dashed lines.median 20% (47 to +27%); F3-F4: median 14%
(58 to +25%)]. In the beta frequency-band, total
power declined (p < 0.05) at central and centro-
temporal electrodes [C3-C4 (Fig. 2c): median 11%
(54 to +21%); C4-T4: median20% (53 to +11%)].
EEG alterations were acquired while the child
was asleep (n = 7) or awake (n = 3). EEG alterations
by pyridoxine-IV during sleep consisted of declined3-C4. The pyridoxine-IV effect on total power in delta (a),
tage of initial value, before pyridoxine administration. At
he total power in the delta (a), theta (b) and beta (c)
arrows. The two PR infants, cases 1 and 3, are separately
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and total power [C3-C4 and C3-T3 in all frequency
bands ( p < 0.02); and F3-F4 in theta frequency-
band]. After exclusion of PR, sleeping TRS-infants
still showed similarly declined amplitude- and
total power-parameters by pyridoxine-IV [C3-C4,
C3-T3 and F3-F4 ( p < 0.05)]. In the three infants
that were awake, EEG alterations did not reach
significance.
In five infants, the procedure of pyridoxine-IV
administration provoked transient movements by
the child (median duration 2 min). In these infants,
EEG-fragments were only selected after transient
movements had disappeared and the infant had
returned to the original state. Comparison between
infants with transient movement induction (n = 5)
and without transient movement induction (n = 5)
did not indicate differences regarding alterations in
amplitude or total power by pyridoxine-IV.
In the total group, relative power was unaffected
by pyridoxine-IV. The delta-, theta- and beta-fre-
quency-bands before pyridoxine-IV were 41, 21 and
12% and after pyridoxine-IV 43, 21 and 12%, respec-
tively. Stratification of the results according to vig-
ilance levels [asleep (n = 7); awake (n = 3)] or
according to transient movements [present
(n = 5); absent (n = 5)], revealed an unaffected rela-
tive power by pyridoxine-IV.Discussion
Among TRS-infants, PD/PR is recognized by the
clinical response after empirical pyridoxine admin-
istration.3 In TRS-infants with high seizure frequen-
cies, pyridoxine-IV may cause prompt attenuation of
seizures and normalization of the EEG, which is
indicative for PD/PR.2,3,15 However, (the time-
and the extent-of) EEG normalization may vary
among PD/PR-infants.2,15 Furthermore, before
EEG alterations can be ascribed to PD/PR, possible
non-specific EEG responses (i.e. independent of PD/
PR) should be excluded first. The present study in
TRS-infants indicates that pyridoxine-IV causes a
non-specific decline in EEG-amplitude and total
power (which is independent of PD/PR). Since we
carefully selected EEG fragments during identical
vigilance states, declined EEG-amplitude and -total
power could not be ascribed to arousal. This was also
confirmed by the identical frequency spectra (rela-
tive power) before and after pyridoxine-IV, which
indirectly reflects continuation of vigilance state. In
young TRS-infants, these ‘‘non-specific’’ effects by
pyridoxine-IV on EEG recordings have never been
described before. In mice, pyridoxine-IV has been
shown to affect EEG background activity afteriatrogenic provocation of convulsions.18 This effect
was explained by relative attenuation of increased
glutamate levels. However, our data in human
TRS-infants do not allow speculations upon expla-
natory anti-glutamergic or GABA-ergic mechanisms.
For instance, pyridoxine-IV did not enhance beta-
activity (which is commonly observed after GABA-
ergic activation) and CSF-GABA concentrations were
normal.
In conclusion, pyridoxine-IV may affect EEG
amplitude and total power in a non-specific way.
In TRS-infants, these non-specific effects after pyr-
idoxine-IV administration should be taken into
account before declined amplitudes and total power
can be attributed to PD/PR.Acknowledgements
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